3 new vacancies:
About the committee
Professor Allan Young MB ChB, MPhil, PhD, FRCPsych, FRCPC
Chair of Mood Disorders, Director of the Centre for
Mental Affective Disorders, Department of Psychological Medicine,
King’s College London, UK
Professor Allan Young holds the Chair of Mood Disorders at
King’s College London where he is also Director of the Centre for
Affective Disorders within the Department of Psychological Medicine
in the Institute of Psychiatry. He has held academic appointments
at the Universities of Oxford, Newcastle upon Tyne (latterly
holding the Chair of General Psychiatry at Newcastle), UBC,
Vancouver, Canada, where he held the Leading Edge Endowment Fund
Endowed Chair in Research in the Department of Psychiatry and was
also the Director of the Institute of Mental Health and Imperial
College London where he held the Chair of Psychiatry and was
Director of the Centre for Mental Health.
Professor Young’s research interests focus on the cause and
treatments for severe psychiatric illnesses, particularly mood
disorders. He has received research grant funding from the UK
Medical Research Council, the Wellcome Trust, the Stanley Medical
Research Institute, and the Canadian Institutes for Heath Research
(CIHR), the National Institutes of Health (USA) and numerous other
funding agencies. He has published over 300 peer-reviewed
publications and a number of books about psychopharmacology and
affective disorders including ‘Bipolar disorders: basic mechanisms
and therapeutic implications’ (2nd Ed.) with JC Soares, and
‘Practical management of bipolar disorder’ with IN Ferrier and E
Michalak (Cambridge University Press, 2010).
Professor Young is a member of a number of editorial boards and
is a member of numerous professional and scientific societies. He
is currently Treasurer of the International Society for Affective
Disorders and Chair of the Psychopharmacology group of the Royal
College of Psychiatrists.
Declaration of Interests:
Employed by King’s College London; Honorary Consultant SLaM (NHS
Paid lectures and advisory boards for all major pharmaceutical
companies with drugs used in affective and related disorders.
No share holdings in pharmaceutical companies.
Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity
study and Aripiprazole Mania Study.
Investigator initiated studies from AZ, Eli Lilly, Lundbeck,
Grant funding (past and present): NIMH (USA); CIHR (Canada);
NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK);
Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK);
UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research
Fund (Canada); MSFHR (Canada); NIHR (UK).
Dr Maria Isaac (Vice-Chair)
Dr Maria Isaac is a Senior Scientific Officer and has been a
member of the Scientific Advice team at the European Medicines
Agency (EMA) for the past seven years. During this time, her
responsibilities have included conducting and overseeing reviews
for a variety of indications including Depression, Schizophrenia,
Alzheimer’s disease (AD), Down syndrome, Autistic Spectrum
Disorders, Parkinson’s disease, Multiple Sclerosis and Pain. She
has over 25 years’ international experience in academic, clinical
and regulatory fields.
A UK citizen and native of Spain, Dr Isaac qualified in medicine
at the University of the Basque Country and obtained a Master’s
degree from Temple University, Philadelphia (USA). She is qualified
as an Adult General Psychiatrist, Pharmaceutical Medicine physician
and as a General Practitioner (UK & Spain).
She has wide experience in molecular biology research as
Research Fellow at University of Pennsylvania and in the Institute
of Psychiatry (University of London, UK), as well as in clinical
research. Her career has focused on novel and innovative
pharmacological treatment, biomarkers, economics and clinical
management of mental illness.
Dr Isaac obtained her PhD in the psychopharmacology of
depression at the University of London , and a Postgraduate
Certificate in Economics (Birkbeck College, University of London,
UK). She was a Consultant Psychiatrist & Co-Director of
Psychopharmacology Evaluation Unit at the South London &
Maudsley NHS Trust in London, and Hon Senior Lecturer at the
Institute of Psychiatry, UK.
As a regulator, Dr Isaac continues to play a pivotal role in the
development of a regulatory qualification procedure that
successfully achieved EMA biomarker qualification. She also is part
of CNSWP formulating CHMP Guidelines. Moreover, Dr. Isaac’s
advisory role facilitates regulatory engagement of different groups
such as C-Path and IMI.
Dr Isaac is fluent in Spanish and English and has a good working
knowledge of French, Italian and Portuguese.
Thomas R. E. Barnes, MD FRCPsych DSc.
I am Professor of Clinical Psychiatry at Imperial College,
London, Honorary Consultant Psychiatrist at the West London Mental
Health NHS Trust, and joint-head of the Prescribing Observatory for
Mental Health (POMH-UK). In 1987, I set up one of the first
tertiary-referral services for treatment-resistant schizophrenia.
The main focus of my clinical research over the last 30 years has
been schizophrenia, with a particular interest in the rational
treatment of the condition. I have led investigations that have
covered psychological and pharmacological treatment interventions
for the condition and investigated antipsychotic drug side effects
(particularly extrapyramidal movement disorders; the reliability,
validity and clinical utility of the Barnes Akathisia Rating Scale
have been independently demonstrated, and it is the scale most
frequently used to assess this condition, world-wide), as well as
phenomenology, neurocognition and comorbid substance use, including
a Wellcome-funded, first-episode psychosis study. My work has
generated over 250 publications. Recent research experience
includes PI for the CUtLASS trial, and chair of the IDMECs for the
BALANCE and CEQUEL trials. I am currently CI for the HTA-funded
ACTIONS and AMICUS trials, PI for the BeneMin study, and chair of
the Trial Steering Committees for the NESS and CIRCLE studies. I am
a past member of the Committee on Safety of Medicines, past Chair
of the Royal College of Psychiatrists’ Special Interest Group in
Psychopharmacology, and past President of the British Association
for Psychopharmacology. I was a member of the NICE schizophrenia
guideline development group (and chair of the pharmacology
subcommittee) in 2002 and for the guideline update in 2009.
I am a Consultant Psychiatrist in the Advanced Interventions
Service, a Scottish National Specialist Service for the assessment
and treatment of chronic, treatment-refractory depression and
Obsessive-Compulsive Disorder (OCD). I work in Dundee and have been
in my current post since 2006. Prior to this, I was a clinical
lecturer in the University of Dundee (2003-2006), and I did his
basic specialist training in Forth Valley.
I was previously Financial Officer for the Royal College of
Psychiatrists in Scotland and I am one of the Academic Secretaries
for the Royal College of Psychiatrists Faculty of General Adult
Psychiatry, responsible for the academic programme of the GAP
I also sit on the steering group overseeing the Scottish Suicide
Information Database (ScotSID). Within NHS Tayside, I co-chaired a
steering group for mental health information systems and continues
to be involved in a range of quality improvement and mental health
His research interests include the neuroimaging of mood
disorders, and the neurosurgical treatment of chronic,
treatment-refractory mood disorders and OCD. He often speaks about
the use of antidepressants, the management of treatment-refractory
mood disorders, and the importance of evidence-based approaches to
the treatment of mental disorder. I am currently involved in
looking at the evidence base for psychological treatments for
severe and/or chronic depression and OCD.
Declaration of Interests:
Employment: I am employed by NHS Scotland to deliver
specialist assessment and treatment (including neurosurgical
treatment) for depression and OCD.
Research: I have been part of two research projects for
which financial support was paid to my institution (University of
Dundee) by medical device companies (Cyberonics, Inc., 2008; and
St. Jude Medical, 2013).
Education and training: I have received support to
attend educational meetings in the last 5 years (Medtronic, 2009),
but no support has been received from companies in the last five
years. I have received expenses associated with speaking from PULSE
and Briefing Media Ltd. (2013). An honorarium for speaking from
Lundbeck (2012) was donated to charity. I have received payment
from the Royal College of Psychiatrists (2012) and the British
Association of Psychopharmacology (2014) to develop online learning
Other payments: I have not received any payments or
consulting fees from pharmaceutical companies in the last five
years and I do not sit on any advisory boards.
Shares and patents: I have no shareholdings, patents,
or financial interests relating to pharmaceutical or medical device
Professor Naomi Fineberg
In the past several years, Dr. Fineberg has
received research support from Lundbeck, Glaxo-SmithKline, European
College of Neuropsychopharmacology (ECNP), Servier, Cephalon, Astra
Zeneca, Medical Research Council (UK), NationalInstitute for Health
Research, Wellcome Foundation. Dr Fineberg has received honoraria
for lectures at scientific meetings from Otsuka, Lundbeck, Servier,
Astra Zeneca, Jazz pharmaceuticals, Bristol Myers Squibb, UK
College of Mental Health Pharmacists, British Association for
Psychopharmacology (BAP). Dr Fineberg has received financial
support to attend scientific meetings from Janssen, Lundbeck,
Servier, Novartis, Bristol Myers Squibb, Cephalon, International
College of Obsessive-Compulsive Spectrum Disorders, International
Society for Behavioural Addiction, ECNP, BAP, World Health
Organization, Royal College of Psychiatrists. Dr Fineberg has
received financial royalties for publications from Oxford
University Press and Taylor and Francis.
Neither she nor any of her immediate family
hold any shares in pharmaceutical companies.
Hollis MBBS BSc PhD DCH FRCPsych
Chris is Professor of Child & Adolescent
Psychiatry at the University of Nottingham and honorary consultant
in Developmental Neuropsychiatry with Nottinghamshire Healthcare
NHS Trust. He trained in psychiatry at the Maudsley Hospital
and completed his PhD at the Institute of Psychiatry. His
clinical and research interests are lifespan neurodevelopmental
disorders including ADHD, Tourette’s, ASD, child and
adolescent-onset psychoses and psychopharmacology.
Chris has recently been appointed Director of
the NIHR MindTech Healthcare Technology Co-operative (HTC) in
mental health and neurodevelopmental disorders and also leads the
NIHR CLAHRC NDL Children and Young People’s research theme.
He was a member of the RAE 2008 panel for psychiatry, clinical
psychology and neuroscience. He chaired the NICE Guideline
Development Group for schizophrenia and psychoses in young people
and was also a member of the NICE Guideline Development Group (GDG)
and Quality Standards Advisory Committee for ADHD. Chris has
been a training program director (TPD) in child and adolescent
psychiatry in Nottingham and member of the CAP Faculty Executive
He is a member of the British Association of
Psychopharmacology (BAP) and organizes and chairs the annual BAP
Certificate Module in child and adolescent psychopharmacology based
Declaration of Interests:
Personal pecuniary: None Personal non-pecuniary: member of BAP;
published research articles and chapters on drug treatments in
children and young people. Non-personal pecuniary: Co-applicant on
a research grant from Shire to investigate driving behavior in
adults with ADHD.
Dr R Hamish McAllister-Williams
BSc, MB, ChB, Ph.D., M.D., FRCPsych
Reader in Clinical Psychopharmacology, Institute of
Neuroscience, Newcastle University and Honorary Consultant
Psychiatrist Regional Affective Disorders Service, Northumberland
Tyne and Wear NHS Foundation Trust.
Dr McAllister-Williams has been employed by Newcastle University
since 1995, initially as a Clinical lecturer, then as an MRC
Clinician Scientist Fellow at Senior Lecturer level and from 2004
as a Reader in Clinical Psychopharmacology. Clinically, he is the
lead consultant in the tertiary level Regional Affective Disorders
Service based in Newcastle. This is the oldest and one of the
largest such service in the UK providing outpatient and inpatient
services for patients with treatment refractory mood disorders.
Referrals to the service are received from across the UK to the
service. Dr McAllister-Williams research focuses on the
pathophysiology and treatment of both bipolar and unipolar
affective disorders. He is a past General Secretary of the British
Association for Psychopharmacology (BAP) and was appointed in 2012
as the BAP Director of Education. He is a major contributor to
their CPD programme.
Declaration of Interests:
Dr McAllister-Williams has received speaker and consultancy
fees, support for attending meetings and independent investigator
led research awards from a number of pharmaceutical companies over
several years including AstraZeneca, Bristol Myers-Squibb,
Cyberonics, Eli Lilly, Ferrer, GlaxoSmithKline, Janssen-Cilag,
Lundbeck, Merck Sharp & Dohme, My Tomorrows, Otsuka, Pfizer,
Roche, Servier, SPIMACO, Sunovion and Wyeth. The vast majority of
such monies have been paid to his employer, Newcastle University.
Neither he nor any of his immediate family hold any shares in, or
have on-going financial relationships with, any pharmaceutical
Scott BSc, MPhil, MD,
MBA, FRCPsych, has been a consultant psychiatrist
in general adult psychiatry at the Royal Edinburgh
Hospital in Edinburgh since 1991. For most of that time he worked
as a sector psychiatrist, but laterally specialized in in-patient
psychiatry. He has been responsible for the ECT clinic at the
Since 1985, Dr Scott has had a research
interest in the neurobiology of ECT and over the years studied the
treatment with the so-called neuroendocrine window,
electroencephalogram, and brain imaging. He has conducted trials of
antidepressant drugs, and written and taught about the
pharmacotherapy of depressive illness and anxiety disorders.
Dr Ahmed Shoka
Consultant in General Adult Psychiatry, North
Essex Partnership University NHS Foundation Trust. I am also an
honorary lecturer at the School of Health & Human sciences ,
Essex University. I have always viewed the art of
psychopharmacology as the sclapel in the hands of a crafty surgeon.
I run a Metabolic Clinic at my Trust to sddress issues of Physical
health for those who suffer from Severe Mental Illness (SMI. I have
a specialised training in the diagnosis and treatment of Adult ADHD
and consequently I run a clinic in this specialised field.
I have a keen interest in Compliance,
Concordance and Adherence when it comes to prescribing. I have
publications in OCD, Depot antipsychotics and Physiccal Health
monitoring. The relationship between Depression, Anxiety and Pain
attracts my attention both clinically and from the research point
of view. I am continuously developing my knowlegde and skills in
the "interface between medical ethics and the law.
Declaration of Interests:
I have no direct business or shares with any pharmaceutical
I receive no grants for research.
I get paid agreed honoraria for delivering educational and not
promotional talks both nationally and internationally.